Applications of Transition Metal Catalysis in Drug Discovery and DevelopmentAn Industrial Perspective
This book focuses on the drug discovery and development applications of transition metal catalyzed processes, which can efficiently create preclinical and clinical drug candidates as well as marketed drugs. The authors pay particular attention to the challenges of transitioning academically-developed reactions into scalable industrial processes. Additionally, the book lays the groundwork for how continued development of transition metal catalyzed processes can deliver new drug candidates. This work provides a unique perspective on the applications of transition metal catalysis in drug discovery and development – it is a guide, a historical prospective, a practical compendium, and a source of future direction for the field.
<p>Preface vii</p> <p>Contributors ix</p> <p>About the Authors xi</p> <p>1 Transition Metal Catalysis in the Pharmaceutical Industry 1<br /><i>Carl A. Busacca, Daniel R. Fandrick, Jinhua J. Song, and Chris H. Senanayake (Boehringer Ingelheim</i> <i>Pharmaceuticals)</i></p> <p>2 Selected Applications of Transition Metal-Catalyzed Carbon–Carbon Cross-Coupling Reactions in the Pharmaceutical Industry 25<br /><i>Hong C. Shen (Roche)</i></p> <p>3 Selected Applications of Pd- and Cu-Catalyzed Carbon–Heteroatom Cross-Coupling Reactions in the Pharmaceutical Industry 97<br /><i>Jingjun Yin (Merck)</i></p> <p>4 Asymmetric Cross-Coupling Reactions 165<br /><i>Vince Yeh (Novartis) and William A. Szabo (Consultant in Drug Development)</i></p> <p>5 Metathesis Reactions 215<br /><i>Oliver R. Thiel (Amgen)</i></p> <p>6 Transition Metal-Catalyzed Synthesis of Five- and Six-Membered Heterocycles 257<br /><i>Cheol K. Chung (Merck) and Matthew L. Crawley (Main Line Health)</i></p> <p>7 Oxidative Catalysis 277<br /><i>Lamont Terrell (GlaxoSmithKline)</i></p> <p>8 Industrial Asymmetric Hydrogenation 315<br /><i>Hans-Ulrich Blaser (Solvias)</i></p> <p>Index 243</p>
<p>“The book will be particularly appreciated by young scientists, especially those aspiring to a future in the pharmaceutical industry, because it shows what kind of problems they will be asked to solve once they start their industrial career.” (<i>ChemMedChem</i>, 1 March 2013)</p> <p>“All chapters are well-written and comprehensive with lots of examples from OPR and D. The book is highly recommended to all process chemists.” (<i>Organic Process Research & Development Journal</i>, 1 November 2012)</p>
<p><b>MATTHEW L. CRAWLEY, P<small>H</small>D,</b> is the Director of the Community Physician Electronic Medical Records Program at Main Line Health. Previously, he has worked as a medicinal chemist at Pfizer and Wyeth Research. Dr. Crawley is an author of more than twenty publications, and his discoveries have resulted in several patents. <p><b>BARRY M. TROST, P<small>H</small>D,</b> is Tamaki Professor of Humanities and Sciences in the Department of Chemistry at Stanford University. Dr. Trost has been elected a Fellow of the American Academy of Sciences and member of the National Academy of Sciences. He has served as chairman of the NIH Medicinal Chemistry Study Section, held over 120 university lectureships, and presented over 260 plenary lectures at national and international meetings.
<p><b>Lays the groundwork for developing promising new drug candidates</b> <p>Drawing on real-life examples, this book demonstrates the applications of transition metal catalysis in drug discovery and development, and its role in the efficient creation of both preclinical and clinical drug candidates as well as commercialized drugs. The authors pay particular attention to the challenges of transitioning reactions developed in academic labs into scalable industrial processes. <p><i>Applications of Transition Metal Catalysis in Drug Discovery and Development</i> begins with a general overview of the use of transition metal catalysis in the pharmaceutical industry. Next, it covers: <ul> <li>Transition metal-catalyzed carbon–carbon cross-coupling reactions</li> <li>Palladium- and copper-catalyzed carbon–heteroatom cross-coupling reactions</li> <li>Asymmetric cross-coupling reactions and metathesis</li> <li>Transition metal-catalyzed synthesis of five- and six-membered heterocycles</li> <li>Oxidative catalysis and industrial asymmetric hydrogenation</li> </ul> <p>Both the editors and authors are internationally recognized experts in drug discovery and development. All authors are scientists from such major pharmaceutical companies as Boehringer Ingelheim, GlaxoSmithKline, Merck, Amgen, and Novartis. Additionally, many of the authors have been responsible for developing the reactions and the drugs discussed in the book, providing readers with firsthand accounts of their discoveries. <p>This remarkable work serves as a guide, historical perspective, and practical compendium, offering pharmaceutical researchers and medicinal chemists a unique perspective on the applications of transition metal catalysis in drug discovery and development. Moreover, the book lays the groundwork for continued development of transition metal-catalyzed processes, setting the stage for new and promising drug candidates.
<p>“’Applications of Transition Metal Catalysis in Drug Discovery and Development’ is a valuable resource in synthetic chemistry which libraries of Chemistry should have, especially those serving medicinal chemists. It captures authoritatively the rich body of information recently generated by many pharmaceutical companies on workable ways to access drug candidates, and constitutes a unique review of modern synthetic practice. The authors (all from industry) also include much relevant academic research. A high proportion of the cited literature is from the last 25 years. It emphasizes catalytic C-C and C-hetero coupling, cyclization, oxidation and reduction reactions. The writing is clear and concise.” —<b>E J Corey</b>, Harvard University</p>
NeuheitenForgotten People, Forgotten Diseases 33,99 €
The End of Love 13,99 €
Infrared Spectroscopy of Symmetric ... 126,99 €
CEH v11 25,99 €
CEH v11 25,99 €